NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55390-0253-01 | 55390-0253 | Mitomycin | Mitomycin | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Sept. 1, 1999 | Nov. 30, 2012 | No Longer Used | |
55390-0291-01 | 55390-0291 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | May 1, 1996 | June 30, 2013 | No Longer Used | |
55390-0808-01 | 55390-0808 | Cytarabine | Cytarabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, subcutaneous, intrathecal | June 28, 1996 | Aug. 31, 2014 | No Longer Used | |
57962-0560-28 | 57962-0560 | Ibrutinib | IMBRUVICA | 560.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 16, 2018 | Feb. 28, 2025 | In Use |
57962-0560-71 | 57962-0560 | Ibrutinib | IMBRUVICA | 560.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb. 6, 2019 | Dec. 31, 2020 | In Use |
59353-0002-10 | 59353-0002 | Epoetin alfa-epbx | RETACRIT | 2000.0 [iU]/mL, 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
59353-0003-10 | 59353-0003 | Epoetin alfa-epbx | RETACRIT | 3000.0 [iU]/mL, 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
59353-0004-10 | 59353-0004 | Epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL, 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
59353-0010-10 | 59353-0010 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL, 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 18, 2018 | In Use | ||
59353-0120-10 | 59353-0120 | Epoetin alfa-epbx | RETACRIT | 20000.0 [iU]/mL, 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Nov. 9, 2020 | In Use | ||
59353-0220-10 | 59353-0220 | Epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL, 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Nov. 9, 2020 | In Use | ||
60429-0265-01 | 60429-0265 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Oct. 26, 2012 | Dec. 31, 2024 | In Use |
60429-0433-01 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | Dec. 31, 2024 | In Use | |
60429-0433-05 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | March 31, 2024 | In Use | |
60505-6166-00 | 60505-6166 | clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 1, 2018 | Jan. 31, 2025 | In Use |
60687-0112-11 | 60687-0112 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 15, 2016 | In Use | ||
60687-0112-21 | 60687-0112 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Feb. 3, 2016 | In Use | ||
60687-0286-11 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 7, 2017 | In Use | |
60687-0286-21 | 60687-0286 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | July 27, 2017 | Sept. 30, 2024 | In Use |
60687-0636-01 | 60687-0636 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 20, 2022 | July 31, 2024 | In Use |
60687-0647-01 | 60687-0647 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 20, 2022 | Aug. 31, 2024 | In Use |
61703-0360-18 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 23, 2022 | In Use | |
61703-0360-22 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 14, 2004 | Oct. 31, 2015 | In Use |
61703-0360-50 | 61703-0360 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Dec. 25, 2009 | Jan. 31, 2016 | In Use |
60687-0718-01 | 60687-0718 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 17, 2022 | In Use |
Found 10,000 results in 6 milliseconds — Export these results